India's Snakebite Crisis Meets Its Match: AI-Designed Antivenom

Snakebite kills an estimated 58,000 people in India every year. That is more deaths than almost any single animal cause of human mortality anywhere on earth, and yet the country has relied for over a century on essentially one antivenom. It is raised against just four species of snake, the cobra, the common krait, Russell's viper, and the saw-scaled viper, using venom collected largely from snakes caught in one region of Tamil Nadu. For patients bitten elsewhere in the country, the treatment often simply does not work.

At the Indian Institute of Science in Bengaluru, Dr Kartik Sunagar's Evolutionary Venomics Lab has spent years mapping how venom composition varies across India's cobras, kraits, and vipers. Now, with support from Anthropic's AI for Science program, his team is using Claude to curate and annotate enormous datasets of venom proteins, accelerating a research pipeline that could produce the first geographically tailored, next-generation antivenoms in Indian history.

A 19th Century Solution to a 21st Century Problem

The antivenom used across most of India today traces its lineage to a manufacturing process developed in the 1890s. Venom is extracted from live snakes and injected, in tiny escalating doses, into horses. The horses develop antibodies, and their plasma is harvested and purified into the final product. It is effective, cheap, and brutal, both for the horses and for patients, who can suffer severe allergic reactions to the horse proteins.

The deeper problem is biological. Venom is not a fixed substance. It evolves rapidly and varies dramatically between populations of the same species. A Russell's viper in Tamil Nadu can produce a meaningfully different venom cocktail than one in Punjab or Maharashtra. Because nearly all commercial venom in India comes from snakes sourced from a single district in Tamil Nadu, the resulting antivenom is mismatched to the bites that occur across most of the subcontinent. Studies from the Sunagar lab and others have documented extensive regional variation and even diet-driven differences within species, explaining why a substantial share of envenoming cases respond poorly to standard treatment.

The Data Problem Hiding in Venom

Understanding venom variation requires what researchers call venomics: sequencing and quantifying every toxin family in every snake population, then comparing thousands of protein profiles across geography, age, diet, and season. A single study can generate millions of data points across mass spectrometry runs, transcriptomes, and proteomic analyses.

This is where the bottleneck lives. Curating that data, matching protein fragments against reference databases, annotating which toxin family each molecule belongs to, and flagging inconsistencies across thousands of records, has traditionally consumed months of highly trained postdoctoral time. It is meticulous, repetitive, expert work. Exactly the kind of work that large language models, given careful scientific oversight, are proving able to compress.

Claude Enters the Lab

In 2025, Anthropic launched its AI for Science program to put Claude in the hands of working research scientists on hard, long-horizon problems. The Sunagar lab's project is among the first AI for Science stories to emerge from India. The team is using Claude to curate and annotate venom omics datasets, checking protein annotations, harmonizing records across studies, and helping researchers query their own data in plain language rather than writing bespoke scripts for every question.

The goal is not to replace the scientists. It is to remove the months of data plumbing between fieldwork and discovery, so the lab can move faster toward its real target: antivenoms designed from the venom data itself, including recombinant and synthetic approaches that could replace horse-derived serum entirely.

What a Next-Generation Antivenom Would Change

The WHO classifies snakebite envenoming as a highest-priority neglected tropical disease. Most victims are rural farmers, laborers, and children, bitten during field work or while walking at night. Many never reach a hospital in time. Of those who do, a significant fraction receive antivenom that only partially neutralizes their symptoms, leading to disability, amputation, chronic kidney damage, or death.

A data-driven antivenom pipeline changes the math in three ways. First, region-specific formulations could match the actual venoms circulating where patients are bitten, dramatically improving neutralization. Second, recombinant antibodies designed against precisely characterized toxins could eliminate the dangerous horse-serum reactions. Third, faster data curation shortens the loop between discovering a venom variant and updating the treatment, a loop that today can take decades.

Why This Story Matters Beyond Snakebite

Snakebite research has been underfunded for a century precisely because its victims are poor and rural. The same is true of many neglected diseases. What makes this moment different is that AI is cheapest exactly where the traditional scientific workforce is scarcest, in the long tail of meticulous data work that big pharma never funded. A lab in Bengaluru, a frontier AI model, and one of India's oldest public health crises are now on the same team.

Fifty-eight thousand deaths a year is not a statistic. It is a farmer in Maharashtra, a child in Bihar, a family that could not afford the trip to the district hospital. If AI-assisted venomics delivers an antivenom that works everywhere in India, it will be one of the clearest demonstrations yet that frontier AI can serve the people the modern world forgot.